These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 12163564

  • 1. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.
    Klein CA, Wilke M, Pool J, Vermeulen C, Blokland E, Burghart E, Krostina S, Wendler N, Passlick B, Riethmüeller G, Goulmy E.
    J Exp Med; 2002 Aug 05; 196(3):359-68. PubMed ID: 12163564
    [Abstract] [Full Text] [Related]

  • 2. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M, Bartsch K, Tschiedel S, Niederwieser D.
    Dtsch Med Wochenschr; 2008 Jul 05; 133(28-29):1511-6. PubMed ID: 18597211
    [Abstract] [Full Text] [Related]

  • 3. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
    Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E.
    Blood; 1999 Apr 01; 93(7):2336-41. PubMed ID: 10090944
    [Abstract] [Full Text] [Related]

  • 4. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
    Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E.
    Blood; 2009 Mar 19; 113(12):2715-22. PubMed ID: 19096014
    [Abstract] [Full Text] [Related]

  • 5. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies.
    Wilke M, Dolstra H, Maas F, Pool J, Brouwer R, Falkenburg JH, Rebello A, Lamers F, Schuuring E, Kluin P, Brasseur F, Goulmy E.
    Hematol J; 2003 Mar 19; 4(5):315-20. PubMed ID: 14502255
    [Abstract] [Full Text] [Related]

  • 6. Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission.
    van der Torren CR, van Hensbergen Y, Luther S, Aghai Z, Rychnavská ZS, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger EM, Goulmy E, Hambach L.
    PLoS One; 2015 Mar 19; 10(3):e0119595. PubMed ID: 25774796
    [Abstract] [Full Text] [Related]

  • 7. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T.
    Leukemia; 2013 Mar 19; 27(3):642-9. PubMed ID: 23079962
    [Abstract] [Full Text] [Related]

  • 8. The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.
    Torikai H, Akatsuka Y, Miyauchi H, Terakura S, Onizuka M, Tsujimura K, Miyamura K, Morishima Y, Kodera Y, Kuzushima K, Takahashi T.
    Bone Marrow Transplant; 2007 Jul 19; 40(2):165-74. PubMed ID: 17530010
    [Abstract] [Full Text] [Related]

  • 9. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand.
    Gillespie G, Mutis T, Schrama E, Kamp J, Esendam B, Falkenburg JF, Goulmy E, Moss P.
    Hematol J; 2000 Jul 19; 1(6):403-10. PubMed ID: 11920221
    [Abstract] [Full Text] [Related]

  • 10. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.
    Mutis T, Blokland E, Kester M, Schrama E, Goulmy E.
    Blood; 2002 Jul 15; 100(2):547-52. PubMed ID: 12091347
    [Abstract] [Full Text] [Related]

  • 11. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors.
    Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E.
    Blood; 2008 Sep 01; 112(5):1844-52. PubMed ID: 18544677
    [Abstract] [Full Text] [Related]

  • 12. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA.
    Mutis T, Ghoreschi K, Schrama E, Kamp J, Heemskerk M, Falkenburg JH, Wilke M, Goulmy E.
    Biol Blood Marrow Transplant; 2002 Sep 01; 8(8):412-9. PubMed ID: 12234166
    [Abstract] [Full Text] [Related]

  • 13. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells.
    Fujii N, Hiraki A, Ikeda K, Ohmura Y, Nozaki I, Shinagawa K, Ishimaru F, Kiura K, Shimizu N, Tanimoto M, Harada M.
    Transplantation; 2002 Apr 15; 73(7):1137-41. PubMed ID: 11965046
    [Abstract] [Full Text] [Related]

  • 14. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
    Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E.
    Nat Med; 2002 Apr 15; 8(4):410-4. PubMed ID: 11927949
    [Abstract] [Full Text] [Related]

  • 15. General T-cell receptor antagonists to immunomodulate HLA-A2-restricted minor histocompatibility antigen HA-1-specific T-cell responses.
    den Haan JM, Mutis T, Blokland E, IJzerman AP, Goulmy E.
    Blood; 2002 Feb 01; 99(3):985-92. PubMed ID: 11807003
    [Abstract] [Full Text] [Related]

  • 16. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E.
    Nat Med; 1999 Jul 01; 5(7):839-42. PubMed ID: 10395333
    [Abstract] [Full Text] [Related]

  • 17. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer.
    Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MH, Goulmy E.
    Haematologica; 2005 Oct 01; 90(10):1415-21. PubMed ID: 16219579
    [Abstract] [Full Text] [Related]

  • 18. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
    Goulmy E.
    Cancer J; 2004 Oct 01; 10(1):1-7. PubMed ID: 15000488
    [Abstract] [Full Text] [Related]

  • 19. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.
    den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF, Engelhard VH, Goulmy E.
    Science; 1998 Feb 13; 279(5353):1054-7. PubMed ID: 9461441
    [Abstract] [Full Text] [Related]

  • 20. Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency.
    Hambach L, Aghai Z, Pool J, Kröger N, Goulmy E.
    J Immunol; 2010 Oct 15; 185(8):4582-9. PubMed ID: 20855877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.